Residency · Residency · Pathology
The Pathology Report as a Clinical Communication Tool
Introduction
The pathology report is the primary deliverable of the pathology laboratory and serves as the definitive record of tissue diagnosis. More than a diagnostic label, the report is a clinical communication document that directly influences staging, treatment planning, prognostication, and eligibility for clinical trials. A poorly structured or incomplete report can lead to treatment delays, inappropriate therapy, or patient harm.
Essential Components of the Pathology Report
Patient and Specimen Identification
Accurate patient identifiers (name, date of birth, medical record number) are mandatory on every report. Specimen designation must match the requisition and container labeling exactly. Laterality (right versus left) must be explicitly stated for paired organs. Discrepancies between clinical information and specimen labeling require resolution before sign-out.
Clinical Information
Relevant clinical history, prior pathology results, and radiologic findings should be documented. The clinical question being asked must be understood by the pathologist to ensure the report addresses it. Prior treatment (neoadjuvant chemotherapy, radiation) affects interpretation and must be noted. Incomplete clinical information should prompt communication with the ordering clinician.
Gross Description
The gross description documents the macroscopic examination of the specimen, including size, weight, color, consistency, and orientation markers. It describes the relationship of the lesion to margins, depth of invasion, and distance to the nearest margin. Inking protocols for margin assessment must be described. Gross photographs supplement the written description for complex specimens.
Microscopic Description
The microscopic description provides the histologic basis for the final diagnosis. It should include tumor type, grade, depth of invasion, lymphovascular invasion, perineural invasion, and margin status. Non-neoplastic tissue abnormalities are described when clinically relevant. In some practice settings, the microscopic description is abbreviated when synoptic elements capture the key findings.
Final Diagnosis
The final diagnosis must be clear, concise, and unambiguous. Diagnoses are listed in order of clinical significance. Tumor classification follows the current WHO classification system. Staging parameters (pTNM) should be included for resection specimens.
Synoptic Reporting and Cancer Protocols
The Role of Cancer Protocols
The College of American Pathologists (CAP) Cancer Protocols provide standardized templates for reporting malignant neoplasms. The synoptic format uses a checklist-style structure with discrete data elements, ensuring completeness. Studies demonstrate that synoptic reporting increases completeness from approximately 60% to over 95% compared to narrative reports. CAP accreditation requires the use of cancer protocols for all applicable specimens.
Key Data Elements
Tumor site and type use standardized terminology from the WHO classification. Histologic grade uses the grading system appropriate to the tumor type (such as Gleason for prostate or Nottingham for breast). Tumor size and extent includes maximum dimension, depth of invasion, and extension into adjacent structures. Margin status reports the distance to the closest margin, with positive margins specified as focal or extensive. Lymph node status includes the number of nodes examined, number positive, size of the largest metastatic deposit, and extranodal extension. Pathologic stage (pTNM) follows the current AJCC staging manual. Additional prognostic and predictive markers include lymphovascular invasion, perineural invasion, tumor deposits, and microsatellite instability status.
Biomarker Reporting
Immunohistochemistry (IHC) results must include the antibody used, scoring system, and interpretation. Breast cancer reporting requires ER, PR, HER2, and Ki-67 status following ASCO/CAP guidelines. Colorectal cancer requires mismatch repair (MMR) protein assessment or microsatellite instability (MSI) testing. Lung adenocarcinoma reporting should address the need for molecular testing (EGFR, ALK, ROS1, PD-L1). Results should be reported using validated scoring criteria with clear positive/negative/equivocal thresholds.
Effective Communication Strategies
Clarity and Precision in Language
Ambiguous terminology such as "consistent with" or "suggestive of" should be avoided when a definitive diagnosis can be rendered. When uncertainty exists, standardized diagnostic categories should be used (such as the Bethesda System for cervical cytology or the Paris System for urine cytology). Abbreviations should be defined on first use, and institution-specific jargon should be avoided. Negative findings that are clinically relevant should be explicitly stated (for example, "No lymphovascular invasion identified").
Critical Value Reporting
Unexpected malignancies, discordant results, and findings requiring urgent clinical action must be communicated directly. Telephone or secure electronic notification to the treating physician with documentation in the report is required. Examples include unexpected malignancy on a specimen submitted as benign, positive margins on a re-excision, and newly identified organisms in an immunocompromised patient. Institutional policies must define which findings constitute critical values.
Addenda and Amended Reports
Addenda append additional information (such as ancillary study results) to a previously signed-out report. Amended reports correct errors in the original diagnosis, and the original text must remain visible with the amendment clearly labeled. The reason for amendment must be documented. Amended reports affecting patient management require direct communication with the clinical team.
Turnaround Time
CAP benchmarks for surgical pathology target 90% of routine cases signed out within 2 working days of accessioning. Biopsies with ancillary testing may have longer turnaround times, but the preliminary morphologic diagnosis should be communicated promptly. Delays in reporting directly impact treatment planning and patient anxiety. Laboratories should track and benchmark turnaround times as a quality metric.
The Report in the Digital Age
Structured Data and Interoperability
Synoptic reporting generates discrete, searchable data elements that can be extracted for cancer registries, quality metrics, and research. HL7 and FHIR standards enable electronic transmission of pathology data across health systems. Integration with electronic health records (EHR) ensures the report is immediately accessible to the clinical team. Standardized data facilitates population-level analytics and quality improvement initiatives.
Integration of Molecular and Genomic Results
Next-generation sequencing (NGS) results must be incorporated into or linked to the surgical pathology report. Variant reporting should follow the Association for Molecular Pathology (AMP) / ASCO / CAP tiered classification system. Clinically actionable mutations must be clearly highlighted. The report should indicate whether the patient may be eligible for targeted therapy or clinical trials based on molecular findings.
Quality Assurance and Error Prevention
Sources of Error in Pathology Reporting
Pre-analytical errors include specimen mislabeling, inadequate fixation, and incorrect clinical information. Analytical errors include misinterpretation of histologic features and failure to order appropriate ancillary studies. Post-analytical errors include transcription errors, incorrect staging, and failure to communicate critical results. Second review (mandatory or selective) reduces diagnostic error rates.
Strategies for Error Reduction
Standardized grossing protocols reduce variability in specimen sampling. Synoptic reporting templates reduce omission of required data elements. Automated alerts flag missing biomarker results or incomplete staging. Regular intradepartmental case conferences and correlation with clinical outcomes support ongoing quality improvement.
Clinical Pearls
Synoptic reporting using CAP Cancer Protocols increases report completeness from approximately 60% to over 95% and is required for accreditation; narrative-only reports for cancer specimens are no longer acceptable. Every pathology report should answer the clinical question being asked; if the clinical information is insufficient to formulate the question, the ordering clinician should be contacted before sign-out. Critical and unexpected findings require direct verbal or documented electronic communication with the treating physician, as the report alone is not sufficient notification. As molecular diagnostics become integral to treatment decisions, pathologists must ensure that actionable genomic findings are clearly highlighted and accessible within or linked to the primary pathology report.
References
- Lankshear S, Srigley J, McGowan T, et al. Standardized synoptic cancer pathology reports -- so what and who cares? Archives of Pathology & Laboratory Medicine. 2013;137(11):1599-1602.
- Ellis DW, Srigley J. Does standardised structured reporting contribute to quality in diagnostic pathology? The importance of evidence-based datasets. Virchows Archiv. 2016;468(1):51-59.
- Valenstein PN. Formatting pathology reports: applying four design principles to improve communication and patient safety. Archives of Pathology & Laboratory Medicine. 2008;132(1):84-94.
- Renshaw AA, Gould EW. Measuring errors in surgical pathology in real-life practice: defining what does and does not matter. American Journal of Clinical Pathology. 2007;127(1):144-152.